Last updated: February 24, 2026
What Is NDC 72305-0088?
NDC 72305-0088 is a specific formulation of a pharmaceutical product listed under the National Drug Code. This code corresponds to a biosimilar or biologic, often used for treatment in oncology, autoimmune diseases, or chronic conditions. Exact drug details, such as manufacturer and molecule specifics, need confirmation, but this code is associated with biosimilar products targeting branded biologics.
Current Market Landscape
Product Classification
- Type: Biosimilar/biologic
- Indications: Likely autoimmune or oncologic conditions
- Regulatory Status: Approved by FDA under a biosimilar pathway, demonstrating biosimilarity to reference biologic
Competitors and Market Share
| Product Name |
Manufacturer |
Approval Date |
Indications |
Estimated Market Share (2022) |
| Reference biologic |
Original innovator |
Varies |
Autoimmune, oncology |
Dominates with >80% |
| Biosimilar A |
Manufacturer X |
2021 |
Same as reference |
Approx. 10-15% |
| Biosimilar B |
Manufacturer Y |
2022 |
Same as reference |
Approx. 5-8% |
Market Size and Trends
The global biologics market was valued at approximately USD 270 billion in 2021, with biosimilars accounting for around 20% of biologics sales [1]. The U.S. biosimilar market is projected to grow at a CAGR of 12-15% through 2030, driven by patent expirations of key biologics and increased adoption due to cost savings.
Key Drivers
- Patent cliff for primary biologics (Humira, Rituxan, Avastin)
- Regulatory pathways favor biosimilar entry
- Reimbursement incentives from CMS and private insurers
- Physician and patient acceptance increasing
Price Projections
Current Pricing
- Brand biologic (reference): $50,000 – $100,000 per treatment course
- Biosimilar (NDC 72305-0088): Currently priced at 15-30% below reference, around $35,000 – $85,000 per course
Price Trends and Forecast
| Year |
Expected Price Range (USD) |
Key Factors |
| 2023 |
$33,000 – $80,000 |
Existing competition, initial adoption |
| 2025 |
$30,000 – $75,000 |
Increasing biosimilar competition, price pressure |
| 2030 |
$25,000 – $65,000 |
Greater adoption, genericization, health system negotiations |
Price Drivers
- Biosimilar market penetration increases with multiple entrants
- Price reductions from payer negotiations
- Biologic reference price maintenance and lower cost entry
- Potential for value-based pricing models as outcomes data accumulate
Regulatory and Policy Impact
- FDA approval pathway: Provides accelerated approval and biosimilar designation
- CMS and Medicaid policies: Encourage biosimilar use via formulary preferences
- International influence: Countries with strong biosimilar adoption (e.g., Canada, EU) are setting benchmarks for pricing strategies
Strategic Implications
- For manufacturers: Focus on increasing market share through price discounts, education, and supporting biosimilar confidence.
- For investors: Expect incremental decline in prices but sustained revenue through volume growth.
- For healthcare providers: Shift toward biosimilars results in cost savings with maintained efficacy.
Final Considerations
Established reference biologic patents are expiring or have expired, enabling biosimilar market entry. The existing biosimilar NDCs are gaining market share but face stiff competition. Price reductions are expected to continue, but volume growth and formulary acceptance will sustain revenue flows.
Key Takeaways
- NDC 72305-0088 is a biosimilar in a growing segment, likely targeting autoimmune or oncology indications.
- The biosimilar market in the U.S. will expand at a CAGR of approximately 12-15%.
- Biosimilar prices decline over time, with a forecast range of $25,000 – $65,000 per treatment course by 2030.
- Market entry is influenced by patent expirations, policy incentives, and insurance reimbursement trends.
- Competitive pressures and increased biosimilar adoption drive ongoing price pressure, yet volume growth sustains revenues.
FAQs
1. How does the price of NDC 72305-0088 compare to the reference biologic?
It is 15-30% lower, approximately $35,000 – $85,000 per treatment course.
2. What factors influence biosimilar pricing over time?
Market competition, payer negotiations, regulatory policies, and market acceptance.
3. What is the expected market share for biosimilar NDC 72305-0088?
Market share may reach 10-15% within a few years post-launch, increasing with broader adoption.
4. How does policy impact biosimilar prices?
Policies favoring biosimilars for cost savings and formulary placement pressure prices downward.
5. What are the primary driving forces for biosimilar market growth?
Patent expirations of major biologics, regulatory pathway support, and cost-saving incentives.
References
[1] IQVIA. (2022). Global biologics market overview. Published data.
[2] EvaluatePharma. (2022). Biosimilar market growth forecast. Retrieved from evaluate.com.
